Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,388
Total Claims
$1.8M
Drug Cost
1,287
Beneficiaries
$1,417
Cost/Patient
Risk Score Breakdown 49/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
+2362%
Opioid rate vs peers
32.2% vs 1.3% avg
-65%
Cost per patient vs peers
$1,417 vs $4,034 avg
-25%
Brand preference vs peers
7.0% vs 9.4% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid prescribing rate is 2,362% above the average for Neurology providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
32.2%
Opioid Rate
3,345
Opioid Claims
$143K
Opioid Cost
15.9%
Long-Acting Rate
This provider's opioid prescribing rate of 32.2% is above the 20% threshold that CMS considers elevated.
Brand vs Generic
Brand: 729 claims · $1.4M
Generic: 9,643 claims · $396K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Erenumab-Aooe | 113 | $148K |
| Immune Globul G/Gly/Iga Avg 46 | 24 | $144K |
| Deutetrabenazine | 15 | $126K |
| Rimegepant Sulfate | 59 | $102K |
| Ubrogepant | 41 | $71K |
| Onabotulinumtoxina | 44 | $68K |
| Eslicarbazepine Acetate | 27 | $63K |
| Clobazam | 14 | $57K |
| Oxycodone Hcl/Acetaminophen | 937 | $42K |
| Galcanezumab-Gnlm | 30 | $33K |
| Atogepant | 24 | $31K |
| Hydrocodone/Acetaminophen | 904 | $31K |
| Dalfampridine | 17 | $26K |
| Oxycodone Myristate | 53 | $21K |
| Brivaracetam | 15 | $21K |
Prescribing Profile
97
Unique Drugs
49.0
Anomaly Score
Patient Profile
69
Avg Age
62%
Female
2.08
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About